COVID-19 Response: Local Logistics     National Effort

A proteomic approach of biomarker candidate discovery for alcoholic liver cirrhosis [Mass Spectrometry - Proteomics Facility].

You are here

COVID-19 Response: Local Logistics     National Effort

TitleA proteomic approach of biomarker candidate discovery for alcoholic liver cirrhosis [Mass Spectrometry - Proteomics Facility].
Publication TypeJournal Article
Year of Publication2018
AuthorsNallagangula KSumanth, Lakshmaiah V, Muninarayana C, Deepa KV, Shashidhar KN
JournalJ Circ Biomark
Volume7
Pagination1849454418788417
Date Published2018 Jan-Dec
ISSN1849-4544
Abstract

Alcoholic liver disease (ALD) progresses from steatosis to alcoholic hepatitis to fibrosis and cirrhosis. Liver biopsy is considered as the gold standard method for diagnosis of liver cirrhosis and provides useful information about damaging process which is an invasive procedure with complications. Existing biomarkers in clinical practice have narrow applicability due to lack of specificity and lack of sensitivity. The objective of this article is to identify proteomic biomarker candidates for alcoholic liver cirrhosis by differential expression analysis between alcoholic liver cirrhotic and healthy subjects. Blood samples were collected from 20 subjects (10 alcoholic liver cirrhosis and 10 healthy) from R. L. Jalapa Hospital and Research Centre, Kolar, Karnataka, India. Differential protein analysis was carried out by two-dimensional electrophoresis after albumin depletion, followed by liquid chromatography-mass spectrometry. The image analysis found 46 spots in cirrhotic gel and 69 spots in healthy gel, of which 14 spots were identified with significant altered expression levels. Based on the protein score and clinical significance, among 14 spots, a total of 28 protein biomarker candidates were identified: 13 with increased expression and 15 with decreased expression were categorized in alcoholic liver cirrhosis compared to healthy subjects. Protein biomarker candidates identified by "-omics" approach based on differential expression between alcoholic liver cirrhotic subjects and healthy subjects may give better insights for diagnosis of ALD. Prioritization of candidates identified is a prerequisite for validation regimen. Biomarker candidates require verification that demonstrates the differential expression will remain detectable by assay to be used for validation.

DOI10.1177/1849454418788417
Alternate JournalJ Circ Biomark
PubMed ID30034555
PubMed Central IDPMC6050617